JCCC encompasses an extensive matrix of laboratory, clinical and population research and clinical care facilities within the Los Angeles metropolitan area. Rather than striving for a centralized cancer center presence, we believe science has evolved to the point where it is feasible and preferable for us to embrace the rich academic environment throughout the entire UCLA campus. Our partnerships with engineering and chemistry, the Molecular Biology Institute, the Broad Stem Cell Research Center and the California Nanosystems Institute, combined with our newly formalized affiliation with Caltech, have made us stronger and more successful in this time of great opportunity in cancer research. In this section, we first describe the Louis Factor Health Sciences Building, which serves as the JCCC's administrative and research focal point. We then summarize the research facilities that are of greatest relevance to the JCCC, beyond traditional department-based laboratory space within the School of Medicine, College of Letters and Science, and School of Engineering. Next, we describe hospitals and clinical facilities that support the clinical and clinical research missions of the JCCC. Finally, we describe other key facilities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016042-39
Application #
8635454
Study Section
Subcommittee G - Education (NCI)
Project Start
1996-12-01
Project End
2018-11-30
Budget Start
2014-03-07
Budget End
2014-11-30
Support Year
39
Fiscal Year
2014
Total Cost
$341,180
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Law, Ivy Ka Man; Jensen, Dane; Bunnett, Nigel W et al. (2016) Neurotensin-induced miR-133α expression regulates neurotensin receptor 1 recycling through its downstream target aftiphilin. Sci Rep 6:22195
Young, Courtney S; Hicks, Michael R; Ermolova, Natalia V et al. (2016) A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells. Cell Stem Cell 18:533-40
Palanichamy, Jayanth Kumar; Tran, Tiffany M; Howard, Jonathan M et al. (2016) RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation. J Clin Invest 126:1495-511
Van Dyk, Kathleen; Ganz, Patricia A; Ercoli, Linda et al. (2016) Measuring cognitive complaints in breast cancer survivors: psychometric properties of the patient's assessment of own functioning inventory. Support Care Cancer 24:4939-4949
Bostean, Georgiana; Crespi, Catherine M; Vorapharuek, Patsornkarn et al. (2016) E-cigarette use among students and e-cigarette specialty retailer presence near schools. Health Place 42:129-136
Aguilera-Sandoval, Christian R; Yang, Otto O; Jojic, Nebojsa et al. (2016) Supranormal thymic output up to 2 decades after HIV-1 infection. AIDS 30:701-11
Bauer, Margaret R; Harris, Lauren N; Wiley, Joshua F et al. (2016) Dispositional and Situational Avoidance and Approach as Predictors of Physical Symptom Bother Following Breast Cancer Diagnosis. Ann Behav Med 50:370-84
Horvath, Steve; Gurven, Michael; Levine, Morgan E et al. (2016) An epigenetic clock analysis of race/ethnicity, sex, and coronary heart disease. Genome Biol 17:171
Ganz, Patricia A; Petersen, Laura; Bower, Julienne E et al. (2016) Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body Study. J Clin Oncol 34:816-24
Dooley, Larissa N; Ganz, Patricia A; Cole, Steve W et al. (2016) Val66Met BDNF polymorphism as a vulnerability factor for inflammation-associated depressive symptoms in women with breast cancer. J Affect Disord 197:43-50

Showing the most recent 10 out of 568 publications